Brought to you by 
Series C for Kalypsys results in $100mm
30 Nov 2006
Executive Summary
Kalypsys, which has a pipeline of clinical compounds for obesity, neuropathic pain, and cancer, grossed $100mm in its Series C financing. Existing shareholder Tavistock Life Sciences, which invested $89mm, was joined by other returning backers Sprout Group, CMEA Ventures, and KT Venture Group.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C for Kalypsys results in $100mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice